$22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT)
Rhea-AI Filing Summary
CORCEPT THERAPEUTICS INC (CORT) received a Rule 144 notice for a proposed sale of up to 175,000 shares of common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc listed as broker. The shares derive from stock option awards dated February 8, 2019 (100,000 shares) and February 10, 2017 (75,000 shares), categorized as equity compensation. Over the prior three months, Maduck reported sales totaling multiple tranches of common stock, including 75,000 shares on May 27, 2026 and several smaller sales through August 14, 2026.
Positive
- None.
Negative
- None.
Key Figures
Shares proposed for sale: 175,000 shares of common stock
Aggregate value of shares: $21,976,448.00
2019 stock option award shares: 100,000 shares
+5 more
8 metrics
Shares proposed for sale
175,000 shares of common stock
Maximum number of CORCEPT THERAPEUTICS INC shares covered by this Rule 144 notice
Aggregate value of shares
$21,976,448.00
Value associated with the 175,000 shares of common stock proposed for sale
2019 stock option award shares
100,000 shares
Common stock underlying stock option award dated February 8, 2019 categorized as equity compensation
2017 stock option award shares
75,000 shares
Common stock underlying stock option award dated February 10, 2017 categorized as equity compensation
Shares sold on May 27, 2026
75,000 shares
Common stock sale by Sean Maduck with aggregate amount $4,918,950.00
Amount from May 27, 2026 sale
$4,918,950.00
Aggregate dollar amount for 75,000 common shares sold on May 27, 2026
Shares sold on June 1, 2026
25,000 shares
Common stock sale by Sean Maduck with aggregate amount $1,755,182.00
Shares sold on July 1, 2026
25,000 shares
Common stock sale by Sean Maduck with aggregate amount $2,208,736.00
Key Terms
Rule 144, Stock Option Award, Equity Compensation, attorney-in-fact
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Award financial
"Common Stock | 02/08/2019 | Stock Option Award | Issuer"
A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.
Equity Compensation financial
"100000 | 08/25/2026 | Equity Compensation"
Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.
attorney-in-fact regulatory
"as a duly authorized representative of STIFEL, as attorney-in-fact for Sean"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
FAQ
What does the Form 144 filing disclose for CORCEPT THERAPEUTICS INC (CORT)?
It discloses a proposed sale under Rule 144 of up to 175,000 shares of CORCEPT THERAPEUTICS INC common stock for the account of officer Sean Maduck, with Stifel Nicolaus & Company Inc as broker, from stock option awards granted in 2017 and 2019.
AI-generated analysis. How Rhea-AI works. Not financial advice.